Presentation is loading. Please wait.

Presentation is loading. Please wait.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Published byHannu-Pekka Tommi Uotila Modified over 5 years ago

Similar presentations

Presentation on theme: "Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q"— Presentation transcript:

1 The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer 
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q. Baggstrom, MD, Feng Gao, PhD, Ramaswamy Govindan, MD  Journal of Thoracic Oncology  Volume 3, Issue 2, Pages (February 2008) DOI: /JTO.0b013e c2c Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Rates of FDG-PET imaging at presentation and rates of stage IV disease for all patients by year of diagnosis. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2c) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Rates of FDG-PET imaging at presentation, grouped by stage and cohort. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2c) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Relative distribution of stages of disease at the time of diagnosis, grouped by cohort. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2c) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Overall survival for stage IV NSCLC patients grouped by cohort. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2c) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 A, Overall survival for stage IV patients according to the use of PET. B, Overall survival for stage III patients according to the use of PET. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2c) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Hedgehog Signaling Pathway and Lung Cancer

Hedgehog Signaling Pathway and Lung Cancer
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Similar presentations

Ads by Google